Patrick Daly

Urban Health Today

Citing that patients with multiple myeloma (MM) have a high risk for thrombosis and thromboembolism, particularly those on immunomodulators, researchers conducted a meta-analysis to define the prognostic significance of thrombosis in MM. The study was presented in <a href="https://tcr.amegroups.com/article/view/73716/html" target="_blank" rel="noopener">Translational Cancer Research</a>.The study&rsquo;s authors found lower levels of &beta;2 microglobulin in patients with MM and venous thromboembolism (VTE). Furthermore, patients with VTE were associated with worse prognoses and mortality rates compared to those without VTE, and patients with arterial thromboembolism had increased mortality compared to those without.<h3>&beta;2 Microglobulin Associated With Thrombosis in Multiple Myeloma</h3>The investigators enrolled 9 studies encompassing 38,047 patients with MM and 6412 recorded thrombotic events, published to PubMed, Embase, Web of Science, Wanfang, and China National Knowledge Infrastructure databases by May 2022.The primary analysis was thrombosis in MM and its association with overall survival (OS), progression-free survival (PFS), event-free survival (EFS), and mortality.According to the report, &beta;2 microglobulin levels modified the incidence of thrombosis in MM with a standard mean difference of -0.09 (95% CI, -0.18 to -0.01; P=.02). In addition, VTE in MM was associated with poorer OS (hazard ratio [HR], 0.79; 95CI, 0.64-0.98; P=.03) and increased early mortality (HR, 2.27; 95% CI, 1.26-4.08; P=.006).PFS and EFS were not significantly different between patients with or without VTE, though arterial thromboembolism was associated with significantly increased mortality at 5 years (HR, 1.89; 95% CI, 133-2.69; P&lt;.01).To conclude, the authors found &beta;2 microglobulin levels may predict thrombosis in MM, and thrombosis was linked to worse survival outcomes. The report suggested that &ldquo;MM patients with high thrombosis risk should receive anticoagulant therapy.&rdquo;Related: <a href="https://urbanhealthtoday.com/post/predicting-cardiovascular-adverse-events-in-multiple-myeloma">Predicting Cardiovascular Adverse Events in Multiple Myeloma</a>

Payton White, BS

How Sleep Quality Influences Risk of Alzheimer’s Disease

Alzheimer's & Dementia

Lou Portero

Hidden Dangers: The Blood Sugar Crisis in Modern Breast Cancer Treatment

Diabetes in Women

New ACG Guidelines Address Critical Gastric Cancer Disparities in Non-White Americans

Gastroenterology

Latest News

Meta-Analysis: The Significance of Thrombosis in Multiple Myeloma

Multiple Myeloma

Based on meta-analysis, researchers reported β2 microglobulin level may predict thrombosis in patients with multiple myeloma.

The Significance of Thrombosis in Multiple Myeloma

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Diabetes

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Public Health

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe